Skip to content

Ascendis Pharma A/S

US · ASND #1127 by market cap Listed 2015
252.73 -3.23 -1.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Quant vs Street three independent views, side by side

StockVane factor grade
D
Momentum strategy signal
Hold
Analyst consensus
Buy

Signals diverge - worth digging into why.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 20 analysts

Buy
Avg price target 320.00 +26.6%
Price target rangecurrent 252.73
Low274.00
Avg320.00
High356.00
Buy 95% Hold 5% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-16 Citi -- Buy 335.00
2026-11-16 Barclays -- Buy 341.00
2026-11-13 TD Cowen -- Buy 352.00
2026-11-13 CCORF -- Hold 274.00
2026-11-13 Wells Fargo -- Buy 330.00
2026-11-13 UBS -- Buy 315.00
2026-11-13 Wedbush -- Buy 346.00
2026-11-13 Morgan Stanley -- Buy 302.00
2026-11-13 Evercore -- Buy 356.00
2026-11-13 Leerink Partners -- Buy 326.00
2026-11-13 H.C. Wainwright -- Buy 335.00
2026-11-13 Barclays -- Buy 341.00
2026-11-12 BofA Securities -- Buy 304.00
2026-11-12 RBC Capital -- Buy 290.00
2026-11-10 TD Cowen -- Buy 352.00
2026-11-09 Morgan Stanley -- Buy 273.00
2026-11-09 H.C. Wainwright -- Buy 344.00
2026-11-02 Morgan Stanley -- Buy 273.00
2026-10-26 CCORF -- Hold 268.00
2026-10-26 Morgan Stanley -- Buy 273.00
2026-10-26 Citi -- Buy 330.00
2026-10-23 Citi -- Buy 330.00
2026-10-21 Morgan Stanley -- Buy 273.00
2026-10-19 Morgan Stanley -- Buy 273.00
2026-10-19 H.C. Wainwright -- Buy 344.00

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-12 -- ±5.16% +3.00% (in line)
2026/Q2 2026-08-13 -- ±6.17% -3.61% (in line)
2026/Q1 2026-05-07 -- ±7.59% +4.34% (in line)
2025/Q4 2026-02-11 After close ±6.18% -1.53% (in line)
2025/Q3 2025-11-12 After close ±8.17% +3.63% (in line)
2025/Q2 2025-08-07 After close ±12.00% +0.60% (in line)
2025/Q1 2025-05-01 After close ±10.36% +2.74% (in line)
2024/Q4 2025-02-12 After close ±7.92% +12.96% (beat)
2024/Q3 2024-11-14 After close ±21.02% +1.79% (in line)
2024/Q2 2024-09-03 After close ±9.85% -11.27% (beat)
2024/Q1 2024-05-02 After close ±21.81% -2.76% (in line)
2023/Q4 2024-02-07 After close ±10.41% -0.03% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Ascendis Pharma A/S discussion 0 comments

Add a comment